Effects of cysteine on the pharmacokinetics of oltipraz in rats with protein-calorie malnutrition

Journal of Pharmaceutical Sciences

Volumn 94, Issue 7, 2005, Pages 1484-1493

  Bae, Soo K ^a   Yang, Si H ^a   Kim, Jin W ^b   Kim, Taekrho ^b   Kwon, Jong W ^c   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b CJ Corporation   (South Korea)

^c Dong A Pharmaceutical Company   (South Korea)

Author keywords

CYP enzymes; Cysteine; Metabolic clearance; Oltipraz; Pharmacokinetics; Protein calorie malnutrition; Rats

Indexed keywords

CYSTEINE; CYTOCHROME P450 1A; CYTOCHROME P450 1A2; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2C11; CYTOCHROME P450 2D1; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; ISOENZYME; LIVER ENZYME; MESSENGER RNA; OLTIPRAZ;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; GENE EXPRESSION; IN VITRO STUDY; MALE; NONHUMAN; PROTEIN CALORIE MALNUTRITION; RAT;

EID: 17144432168     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20369     Document Type: Article

References (35)

1. Denke M, Wilson JD. 1998. Protein and energy malnutrition. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, editors. Principles of internal medicine. 14th ed. New York: McGraw-Hill, pp 452-454.
2. Buchanan N. 1978. Drug kinetics in protein energy malnutrition. S Afr Med J 53:327-330.
3. Krishnaswamy K. 1978. Drug metabolism and pharmacokinetics in malnutrition. Clin Pharmacokinet 3:216-240.
4. Cho MK, Kim YG, Lee MG, Kim SG. 1999. Suppression of rat hepatic cytochrome P450s by protein-calorie malnutrition: Complete or partial restoration by cysteine or methionine supplementation. Arch Biochem Biophys 372:150-158.
5. Kim YG, Cho MK, Kwon JW, Kim SG, Kim SH, Lee MG. 2001. Effects of cysteine on the pharmacokinetics and pharmacodynamics of intravenous and oral azosemide in rats with protein-calorie malnutrition. Life Sci 68:2329-2345.
6. Ahn CY, Kim EJ, Kwon JW, Chung SJ, Kim SG, Shim C-K, Lee MG. 2003. Effects of cysteine on the pharmacokinetics of intravenous clarithromycin in rats with protein-calorie malnutrition. Life Sci 73:1783-1794.
7. Lee AK, Ahn CY, Kim EJ, Kwon JW, Kim SG, Chung SJ, Shim C-K, Lee MG. 2003. Effects of cysteine on the pharmacokinetics of itraconazole in rats with protein-calorie malnutrition. Biopharm Drug Dispos 24:63-70.
8. Kim YG, Cho MK, Kwon JW, Kim D-H, Kim SG, Lee MG. 2003. Effects of cysteine on the pharmacokinetics of intravenous 2-(allylthio)pyrazine, a new chemprotective agent, in rats with protein-calorie malnutrition. Int J Pharm 255:1-11.
9. Bae SK, Lee DY, Lee AK, Kwon JW, Lee I, Chung SJ, Kim SG, Shim C-K, Lee MG. 2004. Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. J Pharm Sci 93:2388-2398.
10. Kim YG, Cho MK, Kwon JW, Kim SG, Lee MG. 2000. Effects of cysteine on the pharmacokinetics of intravenous adriamycin in rats with protein-calorie malnutrition. Res Commun Mol Pathol Pharmacol 107:361-376.
11. Kim YG, Cho MK, Kwon JW, Kim SG, Chung SJ, Shim C-K, Lee MG. 2002. Effects of cysteine on the pharmacokinetics of intravenous chlorzoxazone in rats with protein-calorie malnutrition. Biopharm Drug Dispos 23:121-129.
12. Kim YG, Cho MK, Kwon JW, Kim SG, Chung SJ, Shim C-K, Lee MG. 2001. Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. Int J Pharm 229:45-55.
13. Clapper M. 1998. Chemopreventive activity of oltipraz. Pharmacol Ther 78:17-27.
14. Bueding E, Dolan P, Leroy JP. 1982. The antischistosomal activity of oltipraz. Res Commun Chem Pathol Pharmacol 37:293-303.
15. Primiano T, Egner PA, Sutter TR, Kellof GJ, Roebuds BD, Kensler TW. 1995. Intermittent dosing with oltipraz: Relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione-S-transferases. Cancer Res 55:4319-4324.
16. Kang KW, Kim YG, Cho MK, Bae SK, Kim CW, Lee MG, Kim SG. 2002. Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J 16:1988-1990.
17. Bae SK, Lee SJ, Kim YH, Kim T, Lee MG. 2005. Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous oltipraz in rats. J Pharm Pharmacol (in press).
18. Bae SK, Lee SJ, Lee JY, Lee Y, Lee I, Kim SG, Lee MG. 2004. Pharmacokinetic changes of oltipraz after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. Int J Pharm 275:227-238.
19. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
20. Lineweaver H, Burk D. 1934. The determination of enzyme dissociation constants. J Am Chem Soc 56:658-666.
21. Kim SH, Choi YM, Lee MG. 1993. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1-17.
22. Bae SK, Bu SC, Kim EJ, Kim SH, Kim SG, Lee MG. 2001. Determination of a chemopreventive agent, oltipraz, in rat plasma and urine by high-performance liquid chromatography. Res Commun Mol Pathol Pharmacol 110:133-138.
23. Chiou WL, Nation RL, Peng GW, Huang SM. 1978. Improved micro-scale high-pressure liquid-chromatographic assay of gentamicin in plasma. Clin Chem 24:1846-1847.
24. Christensen RG, Malone W. 1992. Determination of oltipraz in serum by high-performance liquid chromatography with optical absorbance and mass spectrometric detection. J Chromatogr 584:207-212.
25. Chiou WL. 1978. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-546.
26. Gibaldi M, Perrier D. 1982. Pharmacokinetics, 2nd ed. New York: Marcel Dekker.
27. Chiou WL. 1980. New calculation method of mean total body clearance of drugs and its application to dosage regimens. J Pharm Sci 69:90-91.
28. Chiou WL. 1979. New calculation method of mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 68: 1067-1069.
29. Eatman FB, Colburn WA, Boxenbaum HG, Posmanter HN, Weinfeld RE, Ronfeld R, Weissman L, Moore JD, Gibaldi M, Kaplan SA. 1977. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 5:481-494.
30. Bae SK, Lee SJ, Kim YG, Kim SH, Kim JW, Kim T, Lee MG. 2005. Interspecies pharmacokinetics scaling of oltipraz in mice, rats, rabbits, and dogs, and prediction of human pharmacokinetics. Biopharm Drug Dispos 26:99-115.
31. Bae SK, Kim JW, Kim YH, Kim YG, Kim SG, Lee MG. 2005. Hepatic and intestinal first-pass effects of oltipraz in rats. Biopharm. Drug Dispos 26:129-134.
32. Bieder A, Decouvelaere B, Gaillard C, Depaire H, Heusse D, Ledoux C, Lemar M, Leroy JP, Raynaud L, Snozzi C, Gregoire J. 1983. Comparison of the metabolism of oltipraz in the mouse, rat and monkey and in man. Distribution of the metabolites in each species. Arzneim-Forsch/Drug Res 33: 1289-1297.
33. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
34. Mitruka BM, Rawnsley HM. 1982. Clinical biochemical and hematological reference values in normal experimental animals and normal humans, 2nd ed. New York, USA: Masson Publishing, p 67.
35. Lee MG, Choiu WL. 1983. Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640.